Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933060 · ClinicalTrials.gov registry record · Phase 2
Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache
A Phase 2 study of Migraine Headache, sponsored by The Cooper Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02933060 is a Phase 2 study of Migraine Headache that has completed, run by The Cooper Health System. The registered enrollment target is 50 participants, below the 151-participant average among 6 other Migraine Headache trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02933060, a Phase 2 study of Migraine Headache, has completed, sponsored by The Cooper Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether patients in the emergency department with migraine headache who are administered an intravenous fluid bolus will report greater improvement in pain scores than control patients.
Conditions Studied
Interventions
- OTHER Control
- OTHER Normal saline (1000 mL)
Study Locations (1)
New Jersey
- Cooper Univeristy Hospital - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02933060
The ClinicalTrials.gov registry entry for NCT02933060 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 151-participant average among 6 other Migraine Headache trials with a reported enrollment target (67% lower). The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine Headache appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.
NCT02933060 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT02933060 about?
NCT02933060 is a clinical study titled "Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache". The purpose of this study is to determine whether patients in the emergency department with migraine headache who are administered an intravenous fluid bolus will report greater improvement in pain scores than control patients.
What is the current status of trial NCT02933060?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2017-01. Estimated completion is 2017-09-28.
What conditions does trial NCT02933060 study?
This clinical trial studies the following conditions: Migraine Headache.
What interventions are being tested in trial NCT02933060?
The interventions under investigation include: Control (OTHER), Normal saline (1000 mL) (OTHER).
Who is sponsoring clinical trial NCT02933060?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02933060 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine Headache
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Light Exposure, Migraine Outcomes, and Sleep Quality
RECRUITING · NA
-
Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache
COMPLETED · NA
-
TelemEdiciNe-bAsed Cognitive TherapY for Migraines
COMPLETED · NA
-
Efficacy, Tolerability, and Safety of DFN-15
COMPLETED · Phase 3
-
Greater Occipital Nerve Block for Migraine Prophylaxis
COMPLETED · Phase 4
-
Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.